Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 …
…, A Amroun, M Seston, N Ayhan, B Pastorino - JAMA internal …, 2022 - jamanetwork.com
Importance After an infection by SARS-CoV-2, many patients present with persistent
physical symptoms that may impair their quality of life. Beliefs regarding the causes of these …
physical symptoms that may impair their quality of life. Beliefs regarding the causes of these …
Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug
…, S Kaptein, B Pastorino… - Journal of …, 2012 - academic.oup.com
Objectives Infection with yellow fever virus (YFV), the prototypic mosquito-borne flavivirus,
causes severe febrile disease with haemorrhage, multi-organ failure and a high mortality. …
causes severe febrile disease with haemorrhage, multi-organ failure and a high mortality. …
Development of a TaqMan® RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses
B Pastorino, M Bessaud, M Grandadam, S Murri… - Journal of virological …, 2005 - Elsevier
Chikungunya virus (CHIKV), a member of the alphavirus genus, is of considerable public
health concern in Southeast Asian and African countries. However, despite serological …
health concern in Southeast Asian and African countries. However, despite serological …
[HTML][HTML] Prolonged infectivity of SARS-CoV-2 in fomites
We spotted severe acute respiratory syndrome coronavirus 2 on polystyrene plastic, aluminum,
and glass for 96 hours with and without bovine serum albumin (3 g/L). We observed a …
and glass for 96 hours with and without bovine serum albumin (3 g/L). We observed a …
Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral
…, A Tas, G Quérat, B Pastorino… - Journal of …, 2014 - academic.oup.com
Objectives T-705, also known as favipiravir, is a small-molecule inhibitor that is currently in
clinical development for the treatment of influenza virus infections. This molecule also inhibits …
clinical development for the treatment of influenza virus infections. This molecule also inhibits …
Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors
P Gallian, B Pastorino, P Morel, J Chiaroni, L Ninove… - Antiviral research, 2020 - Elsevier
We investigated the distribution of antibodies neutralizing SARS-CoV-2 according to age, sex
or blood group in French blood donors. In 464 samples collected before the emergence of …
or blood group in French blood donors. In 464 samples collected before the emergence of …
[HTML][HTML] Heat inactivation of different types of SARS-CoV-2 samples: what protocols for biosafety, molecular detection and serological diagnostics?
Standard precautions to minimize the risk of SARS-CoV-2 transmission implies that infected
cell cultures and clinical specimens may undergo some sort of inactivation to reduce or …
cell cultures and clinical specimens may undergo some sort of inactivation to reduce or …
[HTML][HTML] Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
…, S Baize, D Sissoko, B Pastorino… - PLoS neglected …, 2017 - journals.plos.org
Background In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with
Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been …
Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been …
In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant
I Delogu, B Pastorino, C Baronti, A Nougairède… - Antiviral research, 2011 - Elsevier
Arbidol (ARB) is an antiviral drug originally licensed in Russia for use against influenza and
other respiratory viral infections. Although a broad-spectrum antiviral activity has been …
other respiratory viral infections. Although a broad-spectrum antiviral activity has been …
[HTML][HTML] Chikungunya virus, cameroon, 2006
We report the isolation of chikungunya virus from a patient during an outbreak of a
denguelike syndrome in Cameroon in 2006. The virus was phylogenetically grouped in the …
denguelike syndrome in Cameroon in 2006. The virus was phylogenetically grouped in the …